N Govindarajan, Managing Director of Aurobindo Pharma, at the company#39;s earnings call on Monday said that the drug maker expects the approval of UB-612 in December or January next year if everything goes according to their plan.Aurobindo Pharma, Vaxxinity seek DCGI nod to begin Phase-2/3 of COVID-19 jab UB-612
N Govindarajan, Managing Director of Aurobindo Pharma, at the company#39;s earnings call on Monday said that the drug maker expects the approval of UB-612 in December or January next year if everything goes according to their plan.
Subscribe to:
Post Comments (Atom)
-
The company, one of the leading manufacturers of soda ash, had initiated the process of carving out its textiles business into GHCL Textile...
-
The BRLLR linked to RBI Repo Rate is revised downwards in line with the reduction on Reserve Bank of India Repo Rate from 5.15 percent to 4...
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
No comments:
Post a Comment